Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Devastated and Resurrected Good Biotech Firms: Theravance Biopharma

December 15, 2021 0

The Market Devastation and Resurrection of Good Biotech Firms Due to the market’s instability that we …

AstraZeneca Granted FDA EUA for Long Acting Antibody Evusheld for Pre-Exposure Prophylaxis of Covid-19

December 9, 2021 0

AstraZeneca Long Acting Antibody Granted FDA EUA for COVID-19 Prevention AstraZeneca (AZN) product Evusheld (tixagevimab co-packaged …

Ionis Pharmaceuticals to Collaborate with AstraZeneca in Treating Transthyretin Amyloidosis with Ionis Product Eplontersen

December 8, 2021 0

Ionis Pharmaceuticals and AstraZeneca in Collaboration to Treat ATTR with Eplontersen Ionis Pharmaceuticals (IONS) announced entering into …

Celldex Therapeutics Dosed the First Patient in a Phase 1 Study of CDX-0159 for Prurigo Nodularis

December 8, 2021 0

Celldex Therapeutics Dosed the First Patient with CDX-0159 for Prurigo Nodularis Celldex Therapeutics (CLDX) announced that …

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron Variant

December 7, 2021 0

GlaxoSmithKline and Vir Biotechnology Sotrovimab Retains In Vitro Activity Against Omicron GlaxoSmithKline plc (GSK) and Vir Biotechnology …

Amgen: Positive Results from Otezla® Phase 3 DISCREET Study in Moderate to Severe Genital Psoriasis

December 2, 2021 0

Amgen Announces Positive Results from Otezla Study for Psoriasis Amgen (AMGN) announced positive top-line results from the …

Great News: Vertex Pharmaceuticals Announced Successful Phase 2 Study Results of VX-147

December 1, 2021 0

Vertex Pharmaceuticals Phase 2 Results of VX-147 Vertex Pharmaceuticals (VRTX) announced today that, in a Phase …

The Omicron Variant and the Bizarre Stock Market Chaos

November 30, 2021 0

The Bizarre Assessment of Biotech Firms in the Stock Market The Clinical-Stage Biotechnology Firms We are …

Ionis Pharmaceuticals Announces that Pfizer Reported Positive Results of Vupanorsen for Cardiovascular Risk Reduction and Severe Hypertriglyceridemia

November 25, 2021 0

Ionis Pharmaceuticals Announced Pfizer Update of Vupanorsen Ionis Pharmaceuticals (IONS) announced that Pfizer's (

Takeda Pharmaceutical Product LIVTENCITY Granted Approval by the FDA

November 25, 2021 0

Takeda Pharmaceutical Granted FDA Approval for LIVTENCITY for Post-Transplant Cytomegalovirus On November 23, 2021 Takeda Pharmaceutical …

The FDA Granted Orphan Drug Designation to Regenxbio Investigational Gene Therapy Drug RGX-202 for Duchenne Muscular Dystrophy

November 23, 2021 0

Regenxbio Granted Orphan Drug Designation for RGX-202 Regenxbio (RGNX) announced the U.S. FDA granted Orphan Drug …

Sangamo Therapeutics: Preliminary Data Shows Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients with Fabry Disease

November 5, 2021 0

Sangamo Therapeutics Preliminary Results Evaluating Isaralgagene Civaparvovec for Fabry Disease Sangamo Therapeutics (SGMO) announced preliminary results from …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Devastated and Resurrected Good Biotech Firms: Theravance Biopharma

AstraZeneca Granted FDA EUA for Long Acting Antibody Evusheld for Pre-Exposure Prophylaxis of Covid-19

Ionis Pharmaceuticals to Collaborate with AstraZeneca in Treating Transthyretin Amyloidosis with Ionis Product Eplontersen

Celldex Therapeutics Dosed the First Patient in a Phase 1 Study of CDX-0159 for Prurigo Nodularis

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron Variant

Amgen: Positive Results from Otezla® Phase 3 DISCREET Study in Moderate to Severe Genital Psoriasis

Great News: Vertex Pharmaceuticals Announced Successful Phase 2 Study Results of VX-147

The Omicron Variant and the Bizarre Stock Market Chaos

Ionis Pharmaceuticals Announces that Pfizer Reported Positive Results of Vupanorsen for Cardiovascular Risk Reduction and Severe Hypertriglyceridemia

Takeda Pharmaceutical Product LIVTENCITY Granted Approval by the FDA

The FDA Granted Orphan Drug Designation to Regenxbio Investigational Gene Therapy Drug RGX-202 for Duchenne Muscular Dystrophy

Let’s Talk About 3 Firms with Important News: Cassava Sciences, Vertex Pharmaceuticals and Gilead Sciences

Arcus Biosciences Stock Price Skyrockets Following Gilead Sciences Decision to Augment Their Partnership

GlaxoSmithKline and Vir Biotechnology Announced U.S. Gov’t Contracts to Purchase $1B of Sotrovimab for COVID-19

Crispr Therapeutics and ViaCyte Inc to Start Trial of First Gene-Edited Cell Replacement Therapy for Type 1Diabetes

Regenxbio and AbbVie Inc Agreement. See Also: Gilead Sciences and Everest Medicines News

Merck and Ridgeback Biotherapeutics: U.S. Government to Purchase 1.4 M Additional Courses of Molnupiravir for COVID-19

Reata Pharmaceuticals Third Quarter Financial Results and Other Company Updates

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at ASH

Sangamo Therapeutics: Preliminary Data Shows Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients with Fabry Disease